

REFERENCE

1. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. *Nat Rev Endocrinol*. 2011;7(9):540-57.
2. Seeman E, Delmas PD. Bone quality--the material and structural basis of bone strength and fragility. *N Engl J Med*. 2006;354(21):2250-61.
3. Seeman E. Bone quality: the material and structural basis of bone strength. *J Bone Miner Metab*. 2008;26(1):1-8.
4. Devlin MJ, Rosen CJ. The bone-fat interface: basic and clinical implications of marrow adiposity. *Lancet Diabetes Endocrinol*. 2015;3(2):141-7.
5. Matsuo K, Irie N. Osteoclast-osteoblast communication. *Arch Biochem Biophys*. 2008;473(2):201-9.
6. Sims NA, Martin TJ. Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted between These Temporary Visitors to the Bone Surface? *Front Endocrinol (Lausanne)*. 2015;6:41.
7. Imai Y, Youn MY, Inoue K, Takada I, Kouzmenko A, Kato S. Nuclear receptors in bone physiology and diseases. *Physiol Rev*. 2013;93(2):481-523.
8. Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions. *J Dent Res*. 2013;92(10):860-7.
9. Rodan GA, Noda M. Gene expression in osteoblastic cells. *Crit Rev Eukaryot Gene Expr*. 1991;1(2):85-98.
10. Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. *Ther Adv Musculoskelet Dis*. 2016;8(6):225-35.
11. Hadjidakis DJ, Androulakis, II. Bone remodeling. *Ann N Y Acad Sci*. 2006;1092:385-96.

12. Matic I, Matthews BG, Wang X, Dymont NA, Worthley DL, Rowe DW, et al. Quiescent Bone Lining Cells Are a Major Source of Osteoblasts During Adulthood. *Stem Cells*. 2016;34(12):2930-42.
13. Miller SC, Jee WS. The bone lining cell: a distinct phenotype? *Calcif Tissue Int*. 1987;41(1):1-5.
14. Everts V, Delaisse JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, et al. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. *J Bone Miner Res*. 2002;17(1):77-90.
15. Franz-Odenaal TA, Hall BK, Witten PE. Buried alive: how osteoblasts become osteocytes. *Dev Dyn*. 2006;235(1):176-90.
16. Chen H, Senda T, Kubo KY. The osteocyte plays multiple roles in bone remodeling and mineral homeostasis. *Med Mol Morphol*. 2015;48(2):61-8.
17. Han Y, Cowin SC, Schaffler MB, Weinbaum S. Mechanotransduction and strain amplification in osteocyte cell processes. *Proc Natl Acad Sci U S A*. 2004;101(47):16689-94.
18. Knothe Tate ML, Adamson JR, Tami AE, Bauer TW. The osteocyte. *Int J Biochem Cell Biol*. 2004;36(1):1-8.
19. Petitprez V, Royer B, Desoutter J, Guiheneuf E, Rigolle A, Marolleau JP, et al. CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study. *Int J Lab Hematol*. 2015;37(1):29-35.
20. Teitelbaum SL, Tondravi MM, Ross FP. Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. *J Leukoc Biol*. 1997;61(4):381-8.
21. Tondravi MM, McKercher SR, Anderson K, Erdmann JM, Quiroz M, Maki R, et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. *Nature*. 1997;386(6620):81-4.
22. Kukita T, Kukita A. Osteoclast differentiation antigen. *Histology and histopathology*. 1996;11(3):821-30.

23. Ishii T, Shimazu Y, Nishiyama I, Kikuta J, Ishii M. The role of sphingosine 1-phosphate in migration of osteoclast precursors; an application of intravital two-photon microscopy. *Mol Cells*. 2011;31(5):399-403.
24. Tsurukai T, Udagawa N, Matsuzaki K, Takahashi N, Suda T. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. *Journal of bone and mineral metabolism*. 2000;18(4):177-84.
25. Engel J, Prockop DJ. The zipper-like folding of collagen triple helices and the effects of mutations that disrupt the zipper. *Annu Rev Biophys Biophys Chem*. 1991;20:137-52.
26. Lees JF, Tasab M, Bulleid NJ. Identification of the molecular recognition sequence which determines the type-specific assembly of procollagen. *EMBO J*. 1997;16(5):908-16.
27. Brandizzi F, Barlowe C. Organization of the ER-Golgi interface for membrane traffic control. *Nat Rev Mol Cell Biol*. 2013;14(6):382-92.
28. Garbes L, Kim K, Riess A, Hoyer-Kuhn H, Beleggia F, Bevot A, et al. Mutations in SEC24D, encoding a component of the COPII machinery, cause a syndromic form of osteogenesis imperfecta. *American journal of human genetics*. 2015;96(3):432-9.
29. Ishida Y, Nagata K. Hsp47 as a collagen-specific molecular chaperone. *Methods Enzymol*. 2011;499:167-82.
30. McLaughlin SH, Bulleid NJ. Molecular recognition in procollagen chain assembly. *Matrix Biol*. 1998;16(7):369-77.
31. Gajko-Galicka A. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. *Acta Biochim Pol*. 2002;49(2):433-41.
32. Bourhis JM, Mariano N, Zhao Y, Harlos K, Exposito JY, Jones EY, et al. Structural basis of fibrillar collagen trimerization and related genetic disorders. *Nat Struct Mol Biol*. 2012;19(10):1031-6.
33. Rich A, Crick FH. The structure of collagen. *Nature*. 1955;176(4489):915-6.

34. Rosen H, Kessler A, Levenson SM. Collagen structure and metabolism. *Surg Forum*. 1960;11:295-7.
35. Prockop DJ, Constantinou CD, Dombrowski KE, Hojima Y, Kadler KE, Kuivaniemi H, et al. Type I procollagen: the gene-protein system that harbors most of the mutations causing osteogenesis imperfecta and probably more common heritable disorders of connective tissue. *Am J Med Genet*. 1989;34(1):60-7.
36. Wirtz MK, Rao VH, Glanville RW, Labhard ME, Pretorius PJ, de Vries WN, et al. A cysteine for glycine substitution at position 175 in an alpha 1 (I) chain of type I collagen produces a clinically heterogeneous form of osteogenesis imperfecta. *Connect Tissue Res*. 1993;29(1):1-11.
37. Lightfoot SJ, Atkinson MS, Murphy G, Byers PH, Kadler KE. Substitution of serine for glycine 883 in the triple helix of the pro alpha 1 (I) chain of type I procollagen produces osteogenesis imperfecta type IV and introduces a structural change in the triple helix that does not alter cleavage of the molecule by procollagen N-proteinase. *J Biol Chem*. 1994;269(48):30352-7.
38. Steinmann B, Superti-Furga A, Royce PM. Imperfect collagenesis in osteogenesis imperfecta. The consequences of cysteine-glycine substitutions upon collagen structure and metabolism. *Ann N Y Acad Sci*. 1988;543:47-61.
39. Forlino A, Marini JC. Osteogenesis imperfecta: prospects for molecular therapeutics. *Mol Genet Metab*. 2000;71(1-2):225-32.
40. Prockop DJ, Kivirikko KI. Heritable diseases of collagen. *N Engl J Med*. 1984;311(6):376-86.
41. Kaneto CM, Lima PS, Zanette DL, Prata KL, Pina Neto JM, de Paula FJ, et al. COL1A1 and miR-29b show lower expression levels during osteoblast differentiation of bone marrow stromal cells from Osteogenesis Imperfecta patients. *BMC Med Genet*. 2014;15:45.
42. Morello R. Osteogenesis imperfecta and therapeutics. *Matrix Biol*. 2018.

43. Forlino A, Marini JC. Osteogenesis imperfecta. *Lancet*. 2016;387(10028):1657-71.
44. Bacon S, Crowley R. Developments in rare bone diseases and mineral disorders. *Ther Adv Chronic Dis*. 2018;9(1):51-60.
45. Sato A, Ouellet J, Muneta T, Glorieux FH, Rauch F. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment. *Bone*. 2016;86:53-7.
46. Bhadada SK, Santosh R, Bhansali A, Upreti V, Dutta P. Osteogenesis imperfecta. *J Assoc Physicians India*. 2009;57:33-6.
47. Stephen J, Shukla A, Dalal A, Girisha KM, Shah H, Gupta N, et al. Mutation spectrum of COL1A1 and COL1A2 genes in Indian patients with osteogenesis imperfecta. *Am J Med Genet A*. 2014;164A(6):1482-9.
48. Hruskova L, Fijalkowski I, Van Hul W, Marik I, Mortier G, Martasek P, et al. Eight mutations including 5 novel ones in the COL1A1 gene in Czech patients with osteogenesis imperfecta. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2016;160(3):442-7.
49. Boudin E, Van Hul W. MECHANISMS IN ENDOCRINOLOGY: Genetics of human bone formation. *Eur J Endocrinol*. 2017;177(2):R69-R83.
50. Mrosk J, Bhavani GS, Shah H, Hecht J, Krüger U, Shukla A, et al. Diagnostic strategies and genotype-phenotype correlation in a large Indian cohort of osteogenesis imperfecta. *Bone*. 2018;110:368-77.
51. Stephen J, Girisha KM, Dalal A, Shukla A, Shah H, Srivastava P, et al. Mutations in patients with osteogenesis imperfecta from consanguineous Indian families. *Eur J Med Genet*. 2015;58(1):21-7.
52. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. *Cochrane Database Syst Rev*. 2016;10:CD005088.
53. Huang X, Huang S, Guo F, Xu F, Cheng P, Ye Y, et al. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro. *Mol Med Rep*. 2016;13(1):613-22.

54. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, et al. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. *Bone*. 1997;20(5):399-404.
55. Martin TJ, Udagawa N. Hormonal regulation of osteoclast function. *Trends Endocrinol Metab*. 1998;9(1):6-12.
56. Martin TJ, Ng KW. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. *J Cell Biochem*. 1994;56(3):357-66.
57. Luckman SP, Hughes DE, Coxon FP, Russell GG, Rogers MJ. JBMR anniversary classic. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998). *J Bone Miner Res*. 2005;20(7):1265-74.
58. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. *Biochem Biophys Res Commun*. 2002;291(3):680-6.
59. Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L, et al. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. *Bone*. 2005;36(1):150-8.
60. Van Beek ER, Lowik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. *Bone*. 2002;30(1):64-70.
61. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. *N Engl J Med*. 2003;349(13):1216-26.
62. Osagie-Clouard L, Sanghani A, Coathup M, Briggs T, Bostrom M, Blunn G. Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation. *Bone Joint Res*. 2017;6(1):14-21.

63. Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. *Cell Signal*. 2009;21(8):1245-54.
64. MacDonald BR, Gallagher JA, Russell RG. Parathyroid hormone stimulates the proliferation of cells derived from human bone. *Endocrinology*. 1986;118(6):2445-9.
65. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. *Bone*. 2008;42(4):806-18.
66. Kobayashi T, Kronenberg H. Minireview: transcriptional regulation in development of bone. *Endocrinology*. 2005;146(3):1012-7.
67. Wagner EF, Karsenty G. Genetic control of skeletal development. *Curr Opin Genet Dev*. 2001;11(5):527-32.
68. Guntur AR, Rosen CJ. Bone as an endocrine organ. *Endocr Pract*. 2012;18(5):758-62.
69. Cappariello A, Ponzetti M, Rucci N. The "soft" side of the bone: unveiling its endocrine functions. *Horm Mol Biol Clin Investig*. 2016;28(1):5-20.
70. Suchacki KJ, Roberts F, Lovdel A, Farquharson C, Morton NM, MacRae VE, et al. Skeletal energy homeostasis: a paradigm of endocrine discovery. *J Endocrinol*. 2017;234(1):R67-R79.
71. Oldknow KJ, MacRae VE, Farquharson C. Endocrine role of bone: recent and emerging perspectives beyond osteocalcin. *J Endocrinol*. 2015;225(1):R1-19.
72. van Niekerk G, Mitchell M, Engelbrecht AM. Bone resorption: supporting immunometabolism. *Biol Lett*. 2018;14(2).
73. Parfitt AM. Morphometry of bone resorption: introduction and overview. *Bone*. 1993;14(3):435-41.
74. Bab IA, Einhorn TA. Polypeptide factors regulating osteogenesis and bone marrow repair. *J Cell Biochem*. 1994;55(3):358-65.

75. Clarke B. Normal bone anatomy and physiology. *Clinical journal of the American Society of Nephrology*. 2008;3(Supplement 3):S131-S9.
76. Sroga GE, Vashishth D. Effects of bone matrix proteins on fracture and fragility in osteoporosis. *Curr Osteoporos Rep*. 2012;10(2):141-50.
77. Frost HM. Tetracycline-based histological analysis of bone remodeling. *Calcif Tissue Res*. 1969;3(3):211-37.
78. Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simoes MJ, Cerri PS. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. *Biomed Res Int*. 2015;2015:421746.
79. Compston JE. Sex steroids and bone. *Physiol Rev*. 2001;81(1):419-47.
80. Eghbali-Fatourehchi GZ, Lamsam J, Fraser D, Nagel D, Riggs BL, Khosla S. Circulating osteoblast-lineage cells in humans. *N Engl J Med*. 2005;352(19):1959-66.
81. Miller SC, Bowman BM, Smith JM, Jee WS. Characterization of endosteal bone-lining cells from fatty marrow bone sites in adult beagles. *Anat Rec*. 1980;198(2):163-73.
82. Komori T. Cell Death in Chondrocytes, Osteoblasts, and Osteocytes. *Int J Mol Sci*. 2016;17(12).
83. Guyatt G, Baumann M, Pauker S, Halperin J, Maurer J, Owens DK, et al. Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force. *Chest*. 2006;129(1):182-7.
84. Knothe Tate ML. "Whither flows the fluid in bone?" An osteocyte's perspective. *J Biomech*. 2003;36(10):1409-24.
85. Dai Q, Han Y, Xie F, Ma X, Xu Z, Liu X, et al. A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation. *J Vis Exp*. 2018(133).

86. Takegahara N, Kim H, Mizuno H, Sakaue-Sawano A, Miyawaki A, Tomura M, et al. Involvement of Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL)-induced Incomplete Cytokinesis in the Polyploidization of Osteoclasts. *J Biol Chem*. 2016;291(7):3439-54.
87. Okahashi N, Koide M, Jimi E, Suda T, Nishihara T. Caspases (interleukin-1beta-converting enzyme family proteases) are involved in the regulation of the survival of osteoclasts. *Bone*. 1998;23(1):33-41.
88. Shoulders MD, Raines RT. Collagen structure and stability. *Annu Rev Biochem*. 2009;78:929-58.
89. Ramachandran GN, Kartha G. Structure of collagen. *Nature*. 1954;174(4423):269-70.
90. Egli J, Erdmann RS, Schmidt PJ, Wennemers H. Effect of N- and C-terminal functional groups on the stability of collagen triple helices. *Chem Commun (Camb)*. 2017;53(80):11036-9.
91. Clements KA, Acevedo-Jake AM, Walker DR, Hartgerink JD. Glycine Substitutions in Collagen Heterotrimers Alter Triple Helical Assembly. *Biomacromolecules*. 2017;18(2):617-24.
92. Kim D, Lee B, Thomopoulos S, Jun YS. The role of confined collagen geometry in decreasing nucleation energy barriers to intrafibrillar mineralization. *Nat Commun*. 2018;9(1):962.
93. Stefanovic B, Stefanovic L, Schnabl B, Bataller R, Brenner DA. TRAM2 protein interacts with endoplasmic reticulum Ca²⁺ pump Serca2b and is necessary for collagen type I synthesis. *Mol Cell Biol*. 2004;24(4):1758-68.
94. Moosa S, Chung BH, Tung JY, Altmuller J, Thiele H, Nurnberg P, et al. Mutations in SEC24D cause autosomal recessive osteogenesis imperfecta. *Clin Genet*. 2015.
95. Fath S, Mancias JD, Bi X, Goldberg J. Structure and organization of coat proteins in the COPII cage. *Cell*. 2007;129(7):1325-36.

96. Jin L, Pahuja KB, Wickliffe KE, Gorur A, Baumgartel C, Schekman R, et al. Ubiquitin-dependent regulation of COPII coat size and function. *Nature*. 2012;482(7386):495-500.
97. Watson RB, Holmes DF, Graham HK, Nusgens BV, Kadler KE. Surface located procollagen N-propeptides on dermatosparactic collagen fibrils are not cleaved by procollagen N-proteinase and do not inhibit binding of decorin to the fibril surface. *J Mol Biol*. 1998;278(1):195-204.
98. Canty-Laird EG, Lu Y, Kadler KE. Stepwise proteolytic activation of type I procollagen to collagen within the secretory pathway of tendon fibroblasts in situ. *Biochem J*. 2012;441(2):707-17.
99. Sauk JJ, Nikitakis N, Siavash H. Hsp47 a novel collagen binding serpin chaperone, autoantigen and therapeutic target. *Front Biosci*. 2005;10:107-18.
100. Makareeva E, Leikin S. Procollagen triple helix assembly: an unconventional chaperone-assisted folding paradigm. *PLoS One*. 2007;2(10):e1029.
101. Martinek N, Shahab J, Sodek J, Ringuette M. Is SPARC an evolutionarily conserved collagen chaperone? *J Dent Res*. 2007;86(4):296-305.
102. Leikina E, Merts MV, Kuznetsova N, Leikin S. Type I collagen is thermally unstable at body temperature. *Proc Natl Acad Sci U S A*. 2002;99(3):1314-8.
103. Weil D, D'Alessio M, Ramirez F, Steinmann B, Wirtz MK, Glanville RW, et al. Temperature-dependent expression of a collagen splicing defect in the fibroblasts of a patient with Ehlers-Danlos syndrome type VII. *J Biol Chem*. 1989;264(28):16804-9.
104. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of Osteogenesis Imperfecta revisited. *Eur J Med Genet*. 2010;53(1):1-5.
105. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. *J Med Genet*. 1979;16(2):101-16.
106. Byers PH, Bonadio JF, Cohn DH, Starman BJ, Wenstrup RJ, Willing MC. Osteogenesis imperfecta: the molecular basis of clinical heterogeneity. *Ann N Y Acad Sci*. 1988;543:117-28.

107. Cohen-Solal L, Bonaventure J, Maroteaux P. Dominant mutations in familial lethal and severe osteogenesis imperfecta. *Hum Genet.* 1991;87(3):297-301.
108. Wallis GA, Sykes B, Byers PH, Mathew CG, Viljoen D, Beighton P. Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible. *J Med Genet.* 1993;30(6):492-6.
109. Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. *N Engl J Med.* 2006;355(26):2757-64.
110. Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. *Nat Genet.* 2007;39(3):359-65.
111. Van Dijk FS, Nesbitt IM, Nikkels PG, Dalton A, Bongers EM, van de Kamp JM, et al. CRTAP mutations in lethal and severe osteogenesis imperfecta: the importance of combining biochemical and molecular genetic analysis. *Eur J Hum Genet.* 2009;17(12):1560-9.
112. Barnes AM, Carter EM, Cabral WA, Weis M, Chang W, Makareeva E, et al. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. *N Engl J Med.* 2010;362(6):521-8.
113. Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. *American journal of human genetics.* 2010;86(3):389-98.
114. Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. *American journal of human genetics.* 2010;86(4):551-9.
115. Lapunzina P, Aglan M, Temtamy S, Caparros-Martin JA, Valencia M, Leton R, et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. *American journal of human genetics.* 2010;87(1):110-4.

116. Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. *American journal of human genetics*. 2011;88(3):362-71.
117. Breslau-Siderius EJ, Engelbert RH, Pals G, van der Sluijs JA. Bruck syndrome: a rare combination of bone fragility and multiple congenital joint contractures. *J Pediatr Orthop B*. 1998;7(1):35-8.
118. van der Slot AJ, Zuurmond AM, Bardoel AF, Wijmenga C, Pruijs HE, Sillence DO, et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. *J Biol Chem*. 2003;278(42):40967-72.
119. Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, et al. Nosology and classification of genetic skeletal disorders: 2010 revision. *Am J Med Genet A*. 2011;155A(5):943-68.
120. Rowe DW, Shapiro JR, Poirier M, Schlesinger S. Diminished type I collagen synthesis and reduced alpha 1(I) collagen messenger RNA in cultured fibroblasts from patients with dominantly inherited (type I) osteogenesis imperfecta. *J Clin Invest*. 1985;76(2):604-11.
121. Genovese C, Rowe D. Analysis of cytoplasmic and nuclear messenger RNA in fibroblasts from patients with type I osteogenesis imperfecta. *Methods Enzymol*. 1987;145:223-35.
122. Genovese C, Brufsky A, Shapiro J, Rowe D. Detection of mutations in human type I collagen mRNA in osteogenesis imperfecta by indirect RNase protection. *J Biol Chem*. 1989;264(16):9632-7.
123. Sykes B, Ogilvie D, Wordsworth P, Anderson, Jones N. Osteogenesis imperfecta is linked to both type I collagen structural genes. *Lancet*. 1986;2(8498):69-72.
124. Lynch JR, Ogilvie D, Priestley L, Baigrie C, Smith R, Farndon P, et al. Prenatal diagnosis of osteogenesis imperfecta by identification of the concordant collagen 1 allele. *J Med Genet*. 1991;28(3):145-50.

125. Willing MC, Cohn DH, Byers PH. Frameshift mutation near the 3' end of the COL1A1 gene of type I collagen predicts an elongated Pro alpha 1(I) chain and results in osteogenesis imperfecta type I. *J Clin Invest.* 1990;85(1):282-90.
126. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. *Cell.* 2002;108(1):17-29.
127. Rauch F, Glorieux FH. Osteogenesis imperfecta. *Lancet.* 2004;363(9418):1377-85.
128. Prockop DJ. Seminars in medicine of the Beth Israel Hospital, Boston. Mutations in collagen genes as a cause of connective-tissue diseases. *N Engl J Med.* 1992;326(8):540-6.
129. van Dijk FS, Cobben JM, Pals G. Osteogenesis imperfecta, normal collagen folding, and lack of cyclophilin B. *N Engl J Med.* 2010;362(20):1940-1; author reply 1-2.
130. Zayzafoon M. Calcium/calmodulin signaling controls osteoblast growth and differentiation. *J Cell Biochem.* 2006;97(1):56-70.
131. Malfait F, Symoens S, Goemans N, Gyftodimou Y, Holmberg E, Lopez-Gonzalez V, et al. Helical mutations in type I collagen that affect the processing of the amino-propeptide result in an Osteogenesis Imperfecta/Ehlers-Danlos Syndrome overlap syndrome. *Orphanet J Rare Dis.* 2013;8:78.
132. Martinez-Glez V, Valencia M, Caparros-Martin JA, Aglan M, Temtamy S, Tenorio J, et al. Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. *Hum Mutat.* 2012;33(2):343-50.
133. Asharani PV, Keupp K, Semler O, Wang W, Li Y, Thiele H, et al. Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. *American journal of human genetics.* 2012;90(4):661-74.
134. Kojima T, Miyaishi O, Saga S, Ishiguro N, Tsutsui Y, Iwata H. The retention of abnormal type I procollagen and correlated expression of HSP 47 in fibroblasts from a patient with lethal osteogenesis imperfecta. *J Pathol.* 1998;184(2):212-8.

135. Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. *Trends Genet.* 2004;20(1):33-43.
136. Sekiya A, Okano-Kosugi H, Yamazaki CM, Koide T. Pigment epithelium-derived factor (PEDF) shares binding sites in collagen with heparin/heparan sulfate proteoglycans. *J Biol Chem.* 2011;286(30):26364-74.
137. Akiyama T, Dass CR, Shinoda Y, Kawano H, Tanaka S, Choong PF. PEDF regulates osteoclasts via osteoprotegerin and RANKL. *Biochem Biophys Res Commun.* 2010;391(1):789-94.
138. Kasaai B, Gaumond MH, Moffatt P. Regulation of the bone-restricted IFITM-like (Bril) gene transcription by Sp and Gli family members and CpG methylation. *J Biol Chem.* 2013;288(19):13278-94.
139. Liu BY, Lu YQ, Han F, Wang Y, Mo XK, Han JX. Effects of the overexpression of IFITM5 and IFITM5 c.-14C>T mutation on human osteosarcoma cells. *Oncol Lett.* 2017;13(1):111-8.
140. Farber CR, Reich A, Barnes AM, Becerra P, Rauch F, Cabral WA, et al. A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor. *J Bone Miner Res.* 2014;29(6):1402-11.
141. Bogan R, Riddle RC, Li Z, Kumar S, Nandal A, Faugere MC, et al. A mouse model for human osteogenesis imperfecta type VI. *J Bone Miner Res.* 2013;28(7):1531-6.
142. Morike M, Brenner RE, Bushart GB, Teller WM, Vetter U. Collagen metabolism in cultured osteoblasts from osteogenesis imperfecta patients. *Biochem J.* 1992;286 (Pt 1):73-7.
143. Marini JC, Reich A, Smith SM. Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation. *Curr Opin Pediatr.* 2014;26(4):500-7.
144. Keller RB, Tran TT, Pyott SM, Pepin MG, Savarirayan R, McGillivray G, et al. Monoallelic and biallelic CREB3L1 variant causes mild and severe osteogenesis imperfecta, respectively. *Genet Med.* 2017.

145. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med.* 2007;357(18):1799-809.
146. Arnett TR, Orriss IR. Metabolic properties of the osteoclast. *Bone.* 2017.
147. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. *Bone.* 1996;18(2):75-85.
148. Pizones J, Plotkin H, Parra-Garcia JI, Alvarez P, Gutierrez P, Bueno A, et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. *J Pediatr Orthop.* 2005;25(3):332-5.
149. Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tato L. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. *J Pediatr.* 2006;149(2):174-9.
150. Biggin A, Munns CF. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta. *Curr Osteoporos Rep.* 2017;15(5):412-8.
151. Marom R, Lee YC, Grafe I, Lee B. Pharmacological and biological therapeutic strategies for osteogenesis imperfecta. *Am J Med Genet C Semin Med Genet.* 2016;172(4):367-83.
152. Antoniazzi F, Monti E, Venturi G, Franceschi R, Doro F, Gatti D, et al. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. *Eur J Endocrinol.* 2010;163(3):479-87.
153. Wang J, Li J, Yang L, Zhou Y, Wang Y. Dose-dependence of PTH-related peptide-1 on the osteogenic induction of MC3T3-E1 cells in vitro. *Medicine (Baltimore).* 2017;96(17):e6637.
154. Chamberlain JR, Schwarze U, Wang PR, Hirata RK, Hankenson KD, Pace JM, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. *Science.* 2004;303(5661):1198-201.
155. Chamberlain JR, Deyle DR, Schwarze U, Wang P, Hirata RK, Li Y, et al. Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. *Mol Ther.* 2008;16(1):187-93.

156. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*. 1970;227(5259):680-5.
157. Basso FG, Silveira Turrioni AP, Hebling J, de Souza Costa CA. Zoledronic acid inhibits human osteoblast activities. *Gerontology*. 2013;59(6):534-41.
158. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. *Bone*. 2000;26(6):581-9.
159. Bhattacharjee A, Bansal M. Collagen structure: the Madras triple helix and the current scenario. *IUBMB life*. 2005;57(3):161-72.
160. Sykes B, Francis MJ, Smith R. Altered relation of two collagen types in osteogenesis imperfecta. *New England Journal of Medicine*. 1977;296(21):1200-3.
161. Haebara H, Yamasaki Y, Kyogoku M. AN AUTOPSY CASE OF OSTEOGENESIS IMPERFECTA CONGENITA—HISTOCHEMICAL and ELECTRON MICROSCOPICAL STUDIES—. *Pathology International*. 1969;19(3):377-94.
162. Bellur S, Jain M, Cuthbertson D, Krakow D, Shapiro JR, Steiner RD, et al. Cesarean delivery is not associated with decreased at-birth fracture rates in osteogenesis imperfecta. *Genet Med*. 2016;18(6):570-6.
163. Arponen H, Makitie O, Waltimo-Siren J. Association between joint hypermobility, scoliosis, and cranial base anomalies in paediatric Osteogenesis imperfecta patients: a retrospective cross-sectional study. *BMC Musculoskeletal Disord*. 2014;15:428.
164. Nagai N, Hosokawa M, Itohara S, Adachi E, Matsushita T, Hosokawa N, et al. Embryonic lethality of molecular chaperone hsp47 knockout mice is associated with defects in collagen biosynthesis. *The Journal of cell biology*. 2000;150(6):1499-506.
165. Ishida Y, Kubota H, Yamamoto A, Kitamura A, Bächinger HP, Nagata K. Type I collagen in Hsp47-null cells is aggregated in endoplasmic reticulum and deficient in N-propeptide processing and fibrillogenesis. *Molecular Biology of the cell*. 2006;17(5):2346-55.

166. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. *J Clin Invest.* 2002;110(9):1293-9.
167. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. *J Bone Miner Res.* 1995;10(10):1478-87.
168. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. *Bone.* 2011;49(1):34-41.
169. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. *N Engl J Med.* 2003;349(5):457-63.
170. van der Horst G, Farih-Sips H, Lowik CW, Karperien M. Multiple mechanisms are involved in inhibition of osteoblast differentiation by PTHrP and PTH in KS483 Cells. *J Bone Miner Res.* 2005;20(12):2233-44.
171. Huang KC, Cheng CC, Chuang PY, Yang TY. The effects of zoledronate on the survival and function of human osteoblast-like cells. *BMC Musculoskeletal Disord.* 2015;16:355.
172. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. *Cancer Res.* 2000;60(21):6001-7.
173. Bilezikian JP. Osteonecrosis of the jaw--do bisphosphonates pose a risk? *N Engl J Med.* 2006;355(22):2278-81.
174. Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, et al. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. *J Bone Joint Surg Am.* 2013;95(4):297-307.
175. Fleisch H. Bisphosphonates: mechanisms of action. *Endocr Rev.* 1998;19(1):80-100.

176. Lindtner RA, Tiaden AN, Genelin K, Ebner HL, Manzl C, Klawitter M, et al. Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss. *Osteoporos Int.* 2014;25(3):1151-61.
177. Favus MJ. Bisphosphonates for osteoporosis. *N Engl J Med.* 2010;363(21):2027-35.
178. Duque G, Li W, Adams M, Xu S, Phipps R. Effects of risedronate on bone marrow adipocytes in postmenopausal women. *Osteoporos Int.* 2011;22(5):1547-53.
179. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. *N Engl J Med.* 1998;339(14):947-52.
180. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. *N Engl J Med.* 2005;353(6):566-75.
181. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. *N Engl J Med.* 2003;349(13):1207-15.
182. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *N Engl J Med.* 2005;353(6):555-65.
183. Dempster DW, Roschger P, Misof BM, Zhou H, Paschalis EP, Alam J, et al. Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study. *J Bone Miner Res.* 2016;31(8):1527-35.
184. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, et al. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. *J Clin Endocrinol Metab.* 2012;97(8):2799-808.